As part of our ongoing series focussing on new registrations in Australia, we have added a product review of Bimekizumab in the treatment of patients with moderate to severe plaque psoriasis.
This review discusses pharmacological properties, mechanism of action and major studies featuring Bimekizumab. It also provides commentary and recommendations from Dr John Frew, staff specialist at Liverpool Hospital, and conjoint lecturer at the University of New South Wales.
Please login below to download this issue (PDF)